Literature DB >> 2487804

Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy.

M D Feher1, D J Betteridge.   

Abstract

There is now considerable evidence that treatment of abnormalities of lipids and lipoproteins reduces the incidence of coronary heart disease (CHD). Treatment of hypertension, another major cardiovascular risk factor, has not been shown to have the same impact on CHD. Possible explanations for this are that cardiovascular risk factors may occur in combination in an individual or that therapy for hypertension has adversely affected one or several of the other risk factors for CHD, thereby offsetting the benefit gained by lowering blood pressure. This article reviews the relationship between lipids, lipoproteins, and coronary heart disease, and the impact of cholesterol lowering on CHD. The evidence that antihypertensive drugs are associated with lipid and lipoprotein abnormalities is introduced by a critical appraisal of the several studies for such evidence. Implications for the treatment of the hypertensive patient are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2487804     DOI: 10.1007/bf00148479

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  51 in total

1.  Receptor-mediated control of cholesterol metabolism.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1976-01-16       Impact factor: 47.728

2.  Beta-adrenoceptor blockade and plasma lipoproteins. Comparison of the effects of propranolol and pindolol on plasma lipoproteins including high-density lipoprotein subfractions.

Authors:  R J Northcote; D Ballantyne
Journal:  Clin Sci (Lond)       Date:  1987-05       Impact factor: 6.124

3.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

Review 4.  Cholesterol and coronary heart disease. A new era.

Authors:  S M Grundy
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

5.  Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

Authors:  M J Martin; S B Hulley; W S Browner; L H Kuller; D Wentworth
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

6.  Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups.

Authors:  R H Grimm; J D Cohen; W M Smith; L Falvo-Gerard; J D Neaton
Journal:  Arch Intern Med       Date:  1985-07

7.  Cholesterol and mortality. 30 years of follow-up from the Framingham study.

Authors:  K M Anderson; W P Castelli; D Levy
Journal:  JAMA       Date:  1987-04-24       Impact factor: 56.272

8.  Treatment of mild hypertension: a five year controlled drug trial. The Oslo study.

Authors:  A Helgeland
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

9.  Effect of trimazosin on serum lipid profiles in hypertensive patients.

Authors:  W Singleton; C R Taylor
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

10.  Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? The Paris Prospective Study.

Authors:  F Cambien; A Jacqueson; J L Richard; J M Warnet; P Ducimetiere; J R Claude
Journal:  Am J Epidemiol       Date:  1986-10       Impact factor: 4.897

View more
  3 in total

Review 1.  Lipid effects of antihypertensive medications.

Authors:  Roderick Deano; Matthew Sorrentino
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

Review 2.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.

Authors:  R I Ogilvie; E D Burgess; J R Cusson; R D Feldman; L A Leiter; M G Myers
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

3.  Management choices for hypertension with coexistent hypercholesterolaemia.

Authors:  M D Feher; A F Lant
Journal:  J R Soc Med       Date:  1991-04       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.